Introduction:
Kaneka Eurogentec announced plans to build a new large scale pharmaceutical grade biologics manufacturing facility in Seraing, Belgium.
Features:
A new state of-the-art facility will be adjacent to its current facility and will produce protein-based drugs, antibody fragments and plasmid DNA for therapeutics.
The construction of the plant is expected to start in autumn of 2017 and will be equipped with a 2, 200L fermenter for the production and purification of new biomedicines using safe microbial strains.
The multi-product facility will include the capability for large scale production using innovative Eurogentec technologies such as the improved production of complex proteins by secretion from yeasts and the production of kilo-scale plasmid DNA for viral and non-viral gene and cell therapies.
The firm will hire 40 additional full time scientific staff, who will be trained in the production of GMP therapeutic products, to work at the plant.
This expansion will serve clients on a worldwide basis biologics manufacturing intended to clinical studies and commercialisation.
Specifications:
| Name | New Pharmaceutical Grade Biologics |
| Location | Seraing, Belgium |
| Type | New Construction |
| Schedule | Expected to begin in autumn of 2017 |
| Parties Involved | Kaneka Eurogentec |
